Carlyle makes new appointments as it completes OCD buy
This article was originally published in Clinica
Ortho-Clinical Diagnostics (OCD) officially transferred from Johnson & Johnson ownership to The Carlyle Group on 30 June, and Carlyle did not waste time appointing new personnel. New CEO Martin Madaus announced several executive suite changes; he himself was named OCD’s new leader in February. Mr Madaus was formerly executive chairman of Quanterix, and has 25 years’ experience in the diagnostics and life science industries.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.